Technical Analysis for ASNS - Arsanis, Inc.

Grade Last Price % Change Price Change
grade F 16.12 2.35% 0.37
ASNS closed up 2.35 percent on Wednesday, April 25, 2018, on 44 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical ASNS trend table...

Date Alert Name Type % Chg
Apr 25 Wide Bands Range Expansion 0.00%
Apr 25 Oversold Stochastic Weakness 0.00%
Apr 24 Narrow Range Bar Range Contraction 2.35%
Apr 24 Wide Bands Range Expansion 2.35%
Apr 24 Oversold Stochastic Weakness 2.35%
Apr 23 Narrow Range Bar Range Contraction 1.70%
Apr 23 Wide Bands Range Expansion 1.70%
Apr 23 Oversold Stochastic Weakness 1.70%
Apr 20 Narrow Range Bar Range Contraction 3.93%
Apr 20 Lower Bollinger Band Walk Weakness 3.93%

Older signals for ASNS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Arsanis, Inc. is a United States-based company engaged in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company's mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500. Its lead program, ASN100, is being studied to prevent hospital-acquired Staphylococcus aureus pneumonia in mechanically ventilated patients heavily colonized with Staphylococcus aureus in their respiratory tracts. Its ASN200 addresses the unmet medical need caused by drug-resistant extra-intestinal escherichia coli infections. Its ASN300 addresses the unmet medical need due to carbapenem-resistant klebsiella pneumoniae infections. Its ASN400 addresses the unmet medical need due to streptococcus pneumoniae, a leading cause of mortality among the elderly. The ASN500 program consisting of potent mAbs targeting respiratory syncytial virus (RSV), is in the discovery phase.
Is ASNS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 28.69
52 Week Low 10.4
Average Volume 42,191
200-Day Moving Average 0.0
50-Day Moving Average 19.054
20-Day Moving Average 19.956
10-Day Moving Average 16.785
Average True Range 1.8687
ADX 25.27
+DI 17.08
-DI 26.9
Chandelier Exit (Long, 3 ATRs ) 20.9739
Chandelier Exit (Short, 3 ATRs ) 20.8161
Upper Bollinger Band 27.0422
Lower Bollinger Band 12.8698
Percent B (%b) 0.23
BandWidth 71.01824
MACD Line -1.4208
MACD Signal Line -0.7046
MACD Histogram -0.7162
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.54
Resistance 3 (R3) 17.43 16.85 17.30
Resistance 2 (R2) 16.85 16.49 16.90 17.22
Resistance 1 (R1) 16.48 16.26 16.67 16.59 17.14
Pivot Point 15.90 15.90 15.99 15.96 15.90
Support 1 (S1) 15.54 15.54 15.72 15.65 15.10
Support 2 (S2) 14.96 15.32 15.01 15.02
Support 3 (S3) 14.59 14.96 14.94
Support 4 (S4) 14.70